Hospital
Singing River Health System
Singing River Health System was paid $81.31M by Medicaid between Jan 2018 and Dec 2024, across 482 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.
33Billing provider infoSINGING RIVER HEALTH SYSTEM
PASCAGOULA, MS 39581
PASCAGOULA, MS 39581
33aNPI1124136593assigned 08/27/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$81.31M
24GClaims2,557,506
24DCodes billed482
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#5 of 77
Median peer was paid$8.23M
This provider vs. median9.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 389,311 | $12.02M | |
| 2019 | 385,612 | $12.77M | |
| 2020 | 357,166 | $11.03M | |
| 2021 | 381,692 | $12.81M | |
| 2022 | 435,193 | $12.82M | |
| 2023 | 363,123 | $11.94M | |
| 2024incomplete | 245,409 | $7.92M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 92,564 | 76,252 | $12.14M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.9% | 49,462 | 39,318 | $8.04M |
| G0378 | Hospital observation service, per hour | 5.3% | 7,848 | 5,677 | $4.33M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 4.6% | 133,059 | 33,295 | $3.72M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.4% | 145,814 | 35,670 | $3.55M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 4.1% | 62,663 | 20,051 | $3.35M |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 4.0% | 134,319 | 32,973 | $3.25M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 3.3% | 9,708 | 8,706 | $2.68M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.1% | 28,082 | 21,232 | $2.54M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.4% | 8,317 | 6,730 | $1.92M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 15,456 | 9,684 | $1.45M |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.5% | 13,230 | 6,516 | $1.25M |
470 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 7,412 | $1.20M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.4% | 7,859 | $1.14M |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 25,420 | $1.06M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 15,185 | $998K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 27,796 | $987K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 10,990 | $856K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 1,553 | $799K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,696 | $701K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 32,440 | $683K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 22,876 | $665K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 19,710 | $659K |
| 71045 | Radiologic examination, chest; single view | <1% | 18,691 | $657K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 122,282 | $634K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 9,805 | $614K |
| 80053 | Comprehensive metabolic panel | <1% | 84,553 | $610K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 32,084 | $525K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 10,256 | $523K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 30,934 | $509K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 13,230 | $483K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 6,871 | $462K |
| 92526 | <1% | 7,256 | $440K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,510 | $437K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,942 | $400K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 28,142 | $396K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,799 | $354K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 29,540 | $349K |
| 97116 | <1% | 19,917 | $341K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,517 | $337K |
| 92523 | <1% | 2,195 | $311K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 122,446 | $304K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,327 | $296K |
| 83880 | <1% | 13,698 | $277K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 10,284 | $274K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 10,278 | $274K |
| 74018 | <1% | 5,727 | $270K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 24,042 | $268K |
| 86900 | <1% | 4,932 | $264K | |
| 29580 | <1% | 3,909 | $255K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,569 | $236K |
| 97162 | <1% | 5,212 | $234K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 16,667 | $233K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,938 | $232K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 39,985 | $229K |
| 97161 | <1% | 4,851 | $224K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,635 | $224K |
| 80061 | Lipid panel | <1% | 23,143 | $219K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,892 | $211K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 2,911 | $207K |
| 73560 | <1% | 5,055 | $201K | |
| 59025 | Fetal non-stress test | <1% | 1,946 | $197K |
| 72100 | <1% | 3,511 | $195K | |
| 93458 | <1% | 210 | $188K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,797 | $185K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 31,580 | $180K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 870 | $179K |
| 86850 | <1% | 3,847 | $176K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,749 | $176K |
| 73630 | <1% | 4,035 | $175K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,609 | $169K |
| 73610 | <1% | 3,539 | $161K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 1,101 | $156K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 7,609 | $156K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,514 | $154K |
| 97014 | <1% | 17,598 | $153K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 224 | $147K |
| 73130 | <1% | 2,876 | $127K | |
| 73030 | <1% | 3,326 | $121K | |
| 80081 | <1% | 1,984 | $119K | |
| 84484 | <1% | 17,320 | $118K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 9,835 | $115K |
| 81001 | <1% | 52,206 | $113K | |
| 76775 | <1% | 1,826 | $110K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 16,708 | $108K |
| 76641 | <1% | 1,856 | $108K | |
| 84703 | <1% | 19,431 | $106K | |
| 73110 | <1% | 2,294 | $105K | |
| 88307 | <1% | 747 | $103K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,173 | $102K |
| 96367 | <1% | 2,787 | $100K | |
| 10061 | <1% | 576 | $99K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,979 | $98K |
| 71250 | <1% | 2,325 | $98K | |
| 76536 | <1% | 1,568 | $94K | |
| 93971 | <1% | 2,080 | $93K | |
| 97533 | <1% | 3,545 | $91K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 821 | $86K |
| 94060 | <1% | 934 | $85K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,069 | $82K |
| 86901 | <1% | 4,920 | $80K | |
| 87070 | <1% | 11,802 | $80K | |
| 74019 | <1% | 1,206 | $80K | |
| 96415 | <1% | 2,145 | $78K | |
| 96417 | <1% | 1,732 | $77K | |
| 87186 | <1% | 12,702 | $77K | |
| 87077 | <1% | 13,324 | $75K | |
| 84439 | <1% | 11,635 | $74K | |
| 12001 | <1% | 672 | $71K | |
| 83550 | <1% | 10,605 | $69K | |
| 88304 | <1% | 2,114 | $69K | |
| 87807 | <1% | 6,330 | $67K | |
| 83690 | <1% | 13,388 | $64K | |
| 73502 | <1% | 1,840 | $64K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 34 | $63K |
| 83540 | <1% | 12,436 | $60K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 581 | $60K |
| 84702 | <1% | 5,481 | $60K | |
| 85027 | <1% | 14,158 | $60K | |
| 73120 | <1% | 1,013 | $58K | |
| 97163 | <1% | 1,158 | $57K | |
| 83735 | <1% | 14,605 | $57K | |
| 73590 | <1% | 1,274 | $57K | |
| 72040 | <1% | 1,390 | $55K | |
| 70360 | <1% | 1,284 | $54K | |
| 72170 | <1% | 832 | $54K | |
| 76801 | <1% | 733 | $53K | |
| 82728 | <1% | 5,859 | $51K | |
| 72082 | <1% | 657 | $51K | |
| 70210 | <1% | 1,202 | $51K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,702 | $50K |
| 83970 | <1% | 2,518 | $50K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 12 | $50K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 391 | $50K |
| 87040 | <1% | 7,732 | $49K | |
| 80074 | <1% | 1,379 | $49K | |
| 86317 | <1% | 1,106 | $49K | |
| 73070 | <1% | 1,105 | $48K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,185 | $48K |
| 87088 | <1% | 8,496 | $47K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 620 | $46K |
| 94762 | <1% | 659 | $46K | |
| 86140 | <1% | 12,314 | $45K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 161 | $45K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 619 | $43K |
| 83655 | <1% | 3,920 | $43K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 155 | $43K |
| 97166 | <1% | 766 | $40K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,766 | $39K |
| 73140 | <1% | 850 | $38K | |
| 86481 | <1% | 590 | $38K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 191 | $37K |
| 12011 | <1% | 377 | $37K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,284 | $37K |
| 97113 | <1% | 1,866 | $36K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 5,323 | $34K |
| 88142 | <1% | 2,203 | $34K | |
| 73090 | <1% | 713 | $34K | |
| 83615 | <1% | 7,267 | $34K | |
| 82607 | <1% | 3,504 | $33K | |
| 72141 | <1% | 311 | $31K | |
| 82962 | <1% | 17,617 | $31K | |
| 87505 | <1% | 425 | $29K | |
| 82784 | <1% | 3,067 | $29K | |
| 83605 | <1% | 4,664 | $29K | |
| 85610 | <1% | 11,187 | $28K | |
| 80076 | <1% | 4,688 | $27K | |
| 97035 | <1% | 3,416 | $26K | |
| 36430 | <1% | 200 | $26K | |
| 74022 | <1% | 445 | $26K | |
| 97010 | <1% | 6,403 | $26K | |
| 93970 | <1% | 314 | $25K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 1,473 | $24K |
| 87075 | <1% | 3,536 | $24K | |
| 84100 | <1% | 6,990 | $24K | |
| 88312 | <1% | 1,171 | $24K | |
| 82248 | <1% | 6,207 | $24K | |
| 87481 | <1% | 546 | $24K | |
| 87081 | <1% | 4,538 | $23K | |
| 84550 | <1% | 6,520 | $22K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 467 | $22K |
| 82378 | <1% | 1,475 | $21K | |
| 82247 | <1% | 5,261 | $20K | |
| 87449 | <1% | 2,177 | $20K | |
| 80069 | <1% | 3,679 | $20K | |
| 96416 | <1% | 97 | $20K | |
| 82570 | <1% | 6,023 | $19K | |
| 82550 | <1% | 4,243 | $18K | |
| 95811 | <1% | 39 | $18K | |
| 87209 | <1% | 1,150 | $17K | |
| 94727 | <1% | 444 | $17K | |
| 85730 | <1% | 4,577 | $17K | |
| 99490 | Ccm add 20min | <1% | 1,213 | $17K |
| 77336 | <1% | 226 | $16K | |
| 86780 | <1% | 1,540 | $16K | |
| 97016 | <1% | 2,167 | $16K | |
| 92585 | <1% | 92 | $15K | |
| 87427 | <1% | 1,752 | $15K | |
| 86038 | <1% | 1,726 | $15K | |
| 97597 | <1% | 226 | $14K | |
| 96523 | <1% | 540 | $14K | |
| 83520 | <1% | 1,295 | $14K | |
| 86665 | <1% | 835 | $14K | |
| 85651 | <1% | 4,533 | $13K | |
| 86480 | <1% | 479 | $13K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 124 | $13K |
| 86703 | <1% | 1,018 | $13K | |
| 97167 | <1% | 191 | $12K | |
| 85379 | <1% | 1,982 | $12K | |
| 82043 | <1% | 3,515 | $12K | |
| 87045 | <1% | 1,663 | $12K | |
| 73552 | <1% | 270 | $12K | |
| 70486 | <1% | 223 | $12K | |
| 87493 | <1% | 421 | $12K | |
| 86803 | <1% | 1,320 | $11K | |
| 82565 | <1% | 3,089 | $11K | |
| 82803 | <1% | 802 | $11K | |
| 71101 | <1% | 170 | $11K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 814 | $11K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 1,736 | $11K |
| 84478 | <1% | 2,387 | $10K | |
| 83630 | <1% | 675 | $10K | |
| 97022 | <1% | 935 | $10K | |
| 87420 | <1% | 842 | $10K | |
| 86920 | <1% | 130 | $10K | |
| 83516 | <1% | 636 | $10K | |
| 10060 | <1% | 101 | $9K | |
| 94726 | <1% | 124 | $9K | |
| 36591 | <1% | 6,777 | $9K | |
| 96401 | <1% | 166 | $9K | |
| 84481 | <1% | 829 | $9K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 115 | $9K |
| 82553 | <1% | 1,093 | $9K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 15,762 | $8K |
| 87177 | <1% | 1,151 | $8K | |
| 86664 | <1% | 661 | $8K | |
| 90686 | <1% | 783 | $8K | |
| 97032 | <1% | 898 | $8K | |
| 82105 | <1% | 664 | $8K | |
| 97024 | <1% | 2,005 | $8K | |
| 76830 | Ultrasound, transvaginal | <1% | 116 | $8K |
| 82465 | <1% | 2,198 | $7K | |
| 12002 | <1% | 81 | $7K | |
| 74178 | <1% | 55 | $7K | |
| 95819 | <1% | 52 | $7K | |
| 92610 | <1% | 197 | $7K | |
| 80165 | <1% | 733 | $7K | |
| 87899 | <1% | 815 | $7K | |
| 85652 | <1% | 4,318 | $7K | |
| 82950 | <1% | 1,852 | $7K | |
| 86738 | <1% | 684 | $7K | |
| 77091 | <1% | 202 | $7K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 46 | $7K |
| 87507 | <1% | 34 | $7K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 206 | $7K |
| 76870 | <1% | 105 | $7K | |
| 82787 | <1% | 477 | $6K | |
| 87205 | <1% | 2,240 | $6K | |
| 86696 | <1% | 390 | $6K | |
| 87641 | <1% | 267 | $6K | |
| 82150 | <1% | 1,256 | $6K | |
| 83721 | <1% | 930 | $6K | |
| 86431 | <1% | 1,466 | $6K | |
| 84156 | <1% | 2,701 | $6K | |
| 77066 | Tomosynthesis, mammo | <1% | 69 | $6K |
| 87640 | <1% | 267 | $5K | |
| A9270 | Non-covered item or service | <1% | 23,569 | $5K |
| 94760 | <1% | 7,845 | $5K | |
| 92650 | <1% | 264 | $5K | |
| 85018 | <1% | 3,598 | $5K | |
| 20610 | <1% | 60 | $5K | |
| 82746 | <1% | 591 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 9,125 | $5K |
| 87210 | <1% | 1,298 | $5K | |
| 84450 | <1% | 1,316 | $5K | |
| 85045 | <1% | 1,472 | $5K | |
| 84460 | <1% | 1,278 | $5K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 241 | $5K |
| 82947 | <1% | 1,413 | $5K | |
| 86663 | <1% | 394 | $4K | |
| 86694 | <1% | 364 | $4K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,332 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 17,206 | $4K |
| 82677 | <1% | 238 | $4K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 70 | $4K |
| 86695 | <1% | 370 | $4K | |
| 93798 | <1% | 175 | $4K | |
| 86308 | <1% | 894 | $4K | |
| 85014 | <1% | 1,603 | $4K | |
| 86336 | <1% | 238 | $3K | |
| 97012 | <1% | 428 | $3K | |
| 87338 | <1% | 281 | $3K | |
| 83525 | <1% | 379 | $3K | |
| 94618 | <1% | 99 | $3K | |
| 93880 | <1% | 42 | $3K | |
| 73060 | <1% | 55 | $3K | |
| 87324 | <1% | 383 | $3K | |
| 84520 | <1% | 1,087 | $3K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 62 | $3K |
| 87335 | <1% | 307 | $3K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 6,588 | $3K |
| 74240 | <1% | 28 | $3K | |
| 82140 | <1% | 247 | $3K | |
| 0002A | <1% | 159 | $3K | |
| 86677 | <1% | 202 | $2K | |
| 73620 | <1% | 62 | $2K | |
| 87046 | <1% | 318 | $2K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 467 | $2K |
| 76882 | <1% | 28 | $2K | |
| 0001A | <1% | 205 | $2K | |
| 81002 | <1% | 1,102 | $2K | |
| 88342 | <1% | 26 | $2K | |
| 84436 | <1% | 354 | $2K | |
| 86774 | <1% | 171 | $2K | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 1,325 | $2K |
| 29125 | <1% | 26 | $2K | |
| 87425 | <1% | 176 | $2K | |
| 72131 | <1% | 42 | $2K | |
| 82270 | <1% | 572 | $2K | |
| 73221 | <1% | 16 | $2K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 3,791 | $2K |
| 73700 | <1% | 42 | $2K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 66 | $2K |
| 84403 | <1% | 100 | $2K | |
| 77080 | <1% | 159 | $2K | |
| 86592 | <1% | 505 | $2K | |
| 89055 | <1% | 397 | $1K | |
| 36592 | <1% | 3,950 | $1K | |
| 99205 | Prolong outpt/office vis | <1% | 16 | $1K |
| 84153 | <1% | 104 | $1K | |
| 97165 | <1% | 31 | $1K | |
| 82272 | <1% | 433 | $1K | |
| 77065 | Tomosynthesis, mammo | <1% | 19 | $1K |
| 86003 | <1% | 81 | $1K | |
| 90653 | <1% | 185 | $1K | |
| 73562 | <1% | 45 | $1K | |
| 84146 | <1% | 62 | $982.86 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 150 | $978.46 |
| 86787 | <1% | 82 | $950.33 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,244 | $903.13 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,151 | $886.24 |
| 72072 | <1% | 14 | $884.84 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,678 | $875.98 |
| 88173 | <1% | 23 | $808.48 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,811 | $797.80 |
| 84165 | <1% | 143 | $773.51 | |
| 87340 | <1% | 117 | $768.82 | |
| 80162 | <1% | 75 | $751.32 | |
| 81003 | <1% | 449 | $726.43 | |
| 83021 | <1% | 44 | $726.32 | |
| 72200 | <1% | 12 | $725.44 | |
| 87581 | <1% | 27 | $706.26 | |
| 87486 | <1% | 27 | $706.25 | |
| 99152 | <1% | 2,501 | $688.63 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 123 | $664.40 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,587 | $642.35 |
| 88313 | <1% | 37 | $609.06 | |
| 86376 | <1% | 57 | $575.72 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,575 | $551.27 |
| G0008 | Administration of influenza virus vaccine | <1% | 556 | $528.44 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 763 | $502.22 |
| 99487 | Ccm add 20min | <1% | 29 | $502.15 |
| 97760 | <1% | 23 | $492.02 | |
| 86769 | <1% | 16 | $456.14 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,586 | $436.80 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,708 | $423.57 |
| 87522 | Neg quan hep c or qual rna | <1% | 16 | $419.46 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,889 | $416.42 |
| 83001 | <1% | 27 | $369.52 | |
| 90670 | <1% | 31 | $369.20 | |
| 90837 | Psychotherapy session, about an hour | <1% | 19 | $367.29 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,940 | $357.78 |
| C1769 | Guide wire | <1% | 1,691 | $351.20 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 538 | $340.52 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 17 | $334.90 |
| G0379 | Direct admission of patient for hospital observation care | <1% | 1,604 | $321.43 |
| 84145 | <1% | 3,842 | $319.59 | |
| 85347 | <1% | 69 | $308.26 | |
| 86334 | <1% | 22 | $304.45 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,295 | $294.65 |
| 93990 | <1% | 13 | $288.97 | |
| 86200 | <1% | 26 | $272.23 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 6,288 | $265.66 |
| 87329 | <1% | 26 | $239.80 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 3,005 | $234.49 |
| 84132 | <1% | 88 | $226.83 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 434 | $226.76 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 326 | $223.28 |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,698 | $221.32 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 6,095 | $218.57 |
| 82785 | <1% | 16 | $213.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 804 | $200.74 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 616 | $199.36 |
| J9045 | Injection, carboplatin, 50 mg | <1% | 21 | $198.85 |
| 86063 | <1% | 39 | $191.15 | |
| 96376 | <1% | 5,104 | $190.49 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,302 | $174.15 |
| 86800 | <1% | 16 | $160.28 | |
| 86704 | <1% | 13 | $145.13 | |
| 82951 | <1% | 13 | $140.73 | |
| 94729 | <1% | 1,274 | $132.82 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 882 | $130.71 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 777 | $127.57 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,620 | $126.26 |
| 96368 | <1% | 956 | $112.92 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,059 | $112.23 |
| 81025 | <1% | 19 | $105.50 | |
| 85041 | <1% | 41 | $103.16 | |
| 99406 | <1% | 154 | $98.15 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 904 | $93.28 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 460 | $90.00 |
| J1815 | Injection, insulin, per 5 units | <1% | 1,899 | $78.17 |
| 90656 | <1% | 18 | $67.21 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,001 | $63.88 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,498 | $63.71 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 159 | $61.98 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 191 | $60.24 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,617 | $59.33 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,192 | $57.37 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 57 | $54.53 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 40 | $52.52 |
| 89051 | <1% | 14 | $50.70 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,226 | $48.55 |
| J7070 | Infusion, d5w, 1000 cc | <1% | 53 | $41.31 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 276 | $39.87 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 514 | $37.28 |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 300 | $35.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 121 | $32.11 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,765 | $31.99 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,781 | $30.99 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 208 | $28.71 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 3,385 | $27.22 |
| 97129 | <1% | 133 | $27.20 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 38 | $23.82 |
| 90694 | <1% | 149 | $22.96 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 28 | $21.32 |
| 86706 | <1% | 18 | $19.34 | |
| 90715 | <1% | 1,168 | $18.32 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 135 | $17.57 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 83 | $15.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 33 | $8.33 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,151 | $5.52 |
| 86364 | <1% | 14 | $4.70 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 77 | $3.00 |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | <1% | 87 | $2.83 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 666 | $2.18 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 248 | $0.82 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 490 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 361 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 70 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 117 | $0.00 |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 290 | $0.00 |
| 76942 | 0% | 276 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 42 | $0.00 |
| 95874 | 0% | 289 | $0.00 | |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 95 | $0.00 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 27 | $0.00 |
| C1874 | Stent, coated/covered, with delivery system | 0% | 32 | $0.00 |
| 90461 | 0% | 31 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 57 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 38 | $0.00 |
| 97127 | 0% | 35 | $0.00 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 12 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 31 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 2,365 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 315 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 1,300 | $0.00 |
| 80050 | General health panel | 0% | 314 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 1,370 | $0.00 |
| 36416 | 0% | 1,667 | $0.00 | |
| 95886 | 0% | 58 | $0.00 | |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | 0% | 23 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 62 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 85 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 51 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 13 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 61 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 32 | $0.00 |
| M0244 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency | 0% | 50 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 15 | $0.00 |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | 0% | 12 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCNEIL, JASON (CFO)
| Provider | Location | Paid |
|---|---|---|
| Singing River Gulfport | Gulfport, MS | $24.98M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.